LCS
LGND icon

Levin Capital Strategies’s Ligand Pharmaceuticals LGND Stock Holding History

Levin Capital Strategies’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-7,547
Closed -$363K – 386
2015
Q1 		$363K Buy
+7,547
New +$289K 0.01% 306

Other funds holding LGND

William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Levin Capital Strategies's LGND Position: Q2 2015 in Review

Levin Capital Strategies sold out of Ligand Pharmaceuticals (LGND) in Q2 2015, closing a stake of 7,547 shares — an estimated $363K sold.

Levin Capital Strategies first reported a position in LGND in Q1 2015 and held it in 1 quarter. The position peaked at $363K in Q1 2015. 215 funds tracked by Wall St. Rank hold LGND as of Q2 2015.

  • Levin Capital Strategies reported no remaining Ligand Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Levin Capital Strategies sold 7,547 Ligand Pharmaceuticals shares in Q2 2015, an estimated $363K.
  • Levin Capital Strategies first reported a position in Ligand Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Levin Capital Strategies's Ligand Pharmaceuticals position peaked at $363K in Q1 2015.
  • 215 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2015.

Based on Levin Capital Strategies's 13F filing for Q2 2015, filed 12 Aug 2015.